WO2011068546A3 - Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling - Google Patents

Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling Download PDF

Info

Publication number
WO2011068546A3
WO2011068546A3 PCT/US2010/003089 US2010003089W WO2011068546A3 WO 2011068546 A3 WO2011068546 A3 WO 2011068546A3 US 2010003089 W US2010003089 W US 2010003089W WO 2011068546 A3 WO2011068546 A3 WO 2011068546A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
multiple myeloma
prognosis
genes
diagnosis
Prior art date
Application number
PCT/US2010/003089
Other languages
French (fr)
Other versions
WO2011068546A2 (en
Inventor
John D. Shaughnessy, Jr.
Bart Barlogie
Yiming Zhou
Original Assignee
Board Of Trustees Of The University Of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of The University Of Arkansas filed Critical Board Of Trustees Of The University Of Arkansas
Publication of WO2011068546A2 publication Critical patent/WO2011068546A2/en
Publication of WO2011068546A3 publication Critical patent/WO2011068546A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a diagnostic or prognostic indicator of multiple myeloma that comprises a global expression profile of total miRNA in the subject with a pattern of 39 up-regulated and 1 down-regulated gene as listed in Table 1. Also provided are methods of diagnosing multiple myleoma in a subject and determining prognosis of a subject with multiple myeloma by demonstrating the subject shows the expression profile of the diagnostic or prognostic indicator and further calculating a risk score and/or a proliferation level based on a group of 70 genes and 11 genes, respectively, such that high scores and levels concomitant with the miRNA expression profile correlates to a diagnosis and/or a poor prognosis. In addition, methods of treating multiple myeloma with a therapeutic inhibitor of an miRNA maturation pathway in the subject and for screening for therapeutic inhibitors that inhibit AGO2 and/or DICER1 genes are provided.
PCT/US2010/003089 2009-12-04 2010-12-03 Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling WO2011068546A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28352109P 2009-12-04 2009-12-04
US61/283,521 2009-12-04

Publications (2)

Publication Number Publication Date
WO2011068546A2 WO2011068546A2 (en) 2011-06-09
WO2011068546A3 true WO2011068546A3 (en) 2011-10-13

Family

ID=44115453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/003089 WO2011068546A2 (en) 2009-12-04 2010-12-03 Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling

Country Status (1)

Country Link
WO (1) WO2011068546A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma
WO2014071205A1 (en) * 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
EP3476949A1 (en) * 2017-10-31 2019-05-01 Centre National De La Recherche Scientifique Prognosis method of multiple myeloma
CN110564852A (en) * 2019-08-06 2019-12-13 中国医学科学院血液病医院(中国医学科学院血液学研究所) MiRNAs expression map model related to human multiple myeloma, construction method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274911A1 (en) * 2006-11-07 2008-11-06 Burington Bart E Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274911A1 (en) * 2006-11-07 2008-11-06 Burington Bart E Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PICHIORRI, F. ET AL.: "MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis", PNAS., vol. 105, no. 35, 26 August 2008 (2008-08-26), pages 12885 - 12890, XP055199305, DOI: doi:10.1073/pnas.0806202105 *
SHAUGHNESSY, J. D. JR. ET AL.: "A validated gene expression model of high-ris k multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1", BLOOD., vol. 109, no. 6, 14 November 2006 (2006-11-14), pages 2276 - 2284 *
UNNO, K. ET AL.: "Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma", LEUKEMIA & LYMPHOMA., vol. 50, no. 11, November 2009 (2009-11-01), pages 1865 - 1871 *

Also Published As

Publication number Publication date
WO2011068546A2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
EP3922731A3 (en) Methods and processes for non-invasive assessment of genetic variations
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
NZ620799A (en) Molecular diagnostic test for cancer
WO2011068546A3 (en) Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling
WO2012135844A3 (en) Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
WO2012174282A3 (en) Biomarker compositions and methods
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
MX341840B (en) Microrna biomarkers indicative of alzheimer's disease.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2014096418A3 (en) Micrornas as therapeutics and biomarkers for epilepsy
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2012160563A3 (en) Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
BRPI0815474A8 (en) METHOD FOR PRODUCING A MALTY-BASED FOOD OR BEVERAGE SUITABLE FOR CONSUMPTION BY AN INDIVIDUAL WITH CELIAC DISEASE
MX2009012315A (en) Methods of identifying genes involved in memory formation using small interfering rna(sirna).
WO2012151390A3 (en) A therapeutic and diagnostic target gene in acute myeloid leukemia
SA112330754B1 (en) Diagnostic method for detection of cardiovascular disease
WO2015012541A3 (en) Kit for early diagnosis of alzheimer's dementia
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
WO2011127202A3 (en) Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
MX2014000283A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10834875

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10834875

Country of ref document: EP

Kind code of ref document: A2